Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 3;15(4):87-92.
doi: 10.1016/j.rpor.2010.06.001. eCollection 2010.

Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment

Krzysztof Małecki  1 , Bogdan Gliński  1 , Anna Mucha-Małecka  1 , Janusz Ryś  2 , Anna Kruczak  2 , Krzysztof Roszkowski  3 , Marta Urbańska-Gąsiorowska  4 , Marcin Hetnał  1
Affiliations

Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment

Krzysztof Małecki et al. Rep Pract Oncol Radiother. .

Abstract

Background: The optimal management of advanced laryngeal and hypopharyngeal cancers (L&HC) must involve consideration of both survival and functional effect of the given treatment approach. Despite over two decades of investigations of several treatment options, including surgery, radiotherapy, chemotherapy or some combinations thereof, little consensus exists as to which treatment offers the best survival, together with functional speech and swallowing.

Aim: To determine predictive and prognostic value of p53, EGFr, Ki-67 in patients with advanced laryngeal and hypopharyngeal cancer, treated with larynx preservation intent.

Materials and methods: Thirty-three patients received 2-3 cycles of induction chemotherapy (ICHT) consisting of cisplatin and fluoruracil and underwent subsequent radical radiotherapy. Immunohistochemical analyzes of p53, EGFr and Ki-67 were performed.

Results: Response to ICHT was obtained in 24 patients (75%). Better response to ICHT was correlated only with EGFr expression (p = 0.04, RR = 1.91). The 5-year loco-regional control (LRC) and disease-specific survival (DSS) rates were 48% and 57%, respectively. The 5-year larynx preservation rate was 68% in responders to ICHT compared to 21% in non-responders (p = 0.02). It was also higher in patients without EGFr expression (but not significantly, p = 0.43).

Conclusion: Lack of EGFr expression is a favorable predictive factor for response to ICHT. Neither p53 nor Ki-67 have predictive and prognostic value in larynx preservation treatment.

Keywords: EGFr; Induction chemotherapy; Ki-67; Larynx preservation; p53.

PubMed Disclaimer

References

    1. Forastiere A., Trotti A., Koch W. Head and neck cancer. N Engl J Med. 2001;345(26):1890–1900. - PubMed
    1. Department of Veterans Affairs Laryngeal Cancer Study Group Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685–1990. - PubMed
    1. Lefebvre J.L., Chevalier D., Luboinski B. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890–899. - PubMed
    1. Forastiere A.A., Goepfert H., Maor M. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–2098. - PubMed
    1. Forastiere A.A., Maor M., Weber R.S. Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx—induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol. 2006;24, abstr:5517.